Vm/Fragment 054 01

Typus Verschleierung

Bearbeiter Hindemith

Gesichtet

Untersuchte Arbeit: Seite: 54, Zeilen: 1ff (komplett)

Quelle: Eicholt 2004 Seite(n): 30, Zeilen: Tabelle

Tabelle 18. Mögliche Nebenwirkungen (NW) während und/oder nach einer IFN-α-Therapie (Abdi EA et al. 1986, Anderlini P et al. 1995, Asnis LA et al. 1995, Chang L et al. 1995, Christian MM et al. 1997, Funk J et al. 1991, Greenfield SM et al. 1994, Guyer DR et al. 1993, Köhler U et al. 2000, Lisker-Melman M et al. 1992, Nouri K et al. 1996, Orlow SJ et al. 1992, Pauluzzi P et al. 1993, Pigatto PD et al. 1991, Purvin VA 1995, Quesada JR et al. 1986, Reinhold U et al. 1997, Salzo [sic] S et al. 1990, Schafer [sic] M et al. 1999, Silver RT et al. 1996, Tartour E et al. 1995, Wölfer LU et al. 1996) Abdi EA, Brien W, Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 36 (5): 515-519, 1986 Abdi EA, Venner PM. Immune thrombocytopenia after α-interferon therapy in patients with cancer. JAMA 255 (14): 1878-1879, 1986 Anderlini P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-α and chemotherapy for metastatic melanoma. Cancer 76 (4): 678-679, 1995 Asnis LA, Gaspari AA. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 33 (3): 393-410, 1995 Chang L, Liranzo M, Bergfeld WF. Cutaneous side effects associated with interferon-α therapy: a review. Cutis 56 (39: 144, 1995 Christian MM, Diven DG, Sanchez RL, Soloway RD. Injections site vasculitis in a patient receiving interferon α for chronic hepatitis C. J Am Acad Dermatol 37 (1): 118-120, 1997 Funk J, Langeland T, Schrumpf E, Iannsen I-LE. Psoriasis induced by interferon α. Br J Dermatol 125 (5): 463-465, 1991 Greenfield SM, Harvey RS, Thompson RP. Rhabdomyolysis after treatment with interferon α. Brit Med J 309 (6953): 512, 1994 Guyer DR, Tiedeman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J. Interferonassociated retinopathy. Arch Ophtalmol 111 (3): 350-356, 1993 Köhler U, Linse F, Sebastian G, Meurer M. Akute Rhabdomyolyse als Komplikation einer Interferon-α Therapie bei erythrodermer Mycosis fungoides. Zeitschrift für Hautkrankheiten; H+G 3 (75): 138-141, 2000 Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon α. Gastroenterology 102 (6): 2155-2160, 1992 Nouri K, Valor P, Rodriguez FM, Kerdel FA. Interferon α-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma. J Am Acad Dermatol 35 (2 Pt 1): 269-270, 1996 Orlow SJ, Friedman-Kien AE. Cutaneous ulcerations secondary to interferon α therapy of Kaposi´s sarcoma. Arch Dermatol 128 (4): 566, 1992 Pauluzzi P, Kokelj F, Perkan V, Pozzato G, Moretti M. Psoriasis exacerbation induced by interferon α. Report of two cases. Acta Derm Venerol 73 (5): 395, 1993 Pigatto PD, Bigardi A, Legori A, Altomare GF, Riboldi A .Allergic contact dermatitis from beta-interferon in eyedrops. Contact Dermatitis 25 (3): 199- 200, 1991 Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113 (8): 1041-1044, 1995 Quesada JR, Gutterman JU. Psoriasis and α-interferon. Lancet 1 (8496): 1466-1468, 1986 Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 4 (2): 234-243, 1986 Reinhold U, Hartl C, Hering R, Hoeft A, Kreysel HW.Fatal rhabdomyolysis and multiple organ failure with adjuvant high-dose interferon α in malignant melanoma. Lancet 349 (9051): 540-541, 1997 Scalzo S, Gengaro A, Boccoli G, Masciulli R, Giannella G, Salvo G. Primary hypothyroidism associated with IL-2 and INFα2-therapy of melanoma and renal carcinoma. Eur J Cancer 26 (11-12): 1152-1156, 1990 Schäfer M, Messer T, Wegner U, Schmid-Wendtner M, Volkenandt M. Psychiatrische Nebenwirkungen während adjuvanter Therapien mit Interferonalpha bei Patienten mit malignen Melanomen: Klinische Einschätzung sowie diagnostische und therapeutische Möglichkeiten. Hautarzt 50 (9): 654-658, 1999 Silver RT, Szatrowski TP, Peterson B, Powell B, Larson R, Stock W, Arthur D, Schiffer C, Bloomfield CD. Combined α Interferon (rINFα2b) and low dose Cytosine Arabinoside (ARA-C) for PH + chronic phase chronic myeloid leukemia. Blood 88; 638 (suppl. 1), 1996 Tartour E, Schlumberger M, Dorval T, Baudin E, Fridman WH. Endocrine involvement in immunotherapy. Ann Endocrinol 56 (2): 143-148, 1995 Wölfer LU, Goerdt S, Schröder K, Zouboulis CC, Orfanos CE. Interferon-α- induzierte Psoriasis vulgaris. Hautarzt 47 (2): 124-128, 1996

Tabelle 16 Mögliche Nebenwirkungen während und/oder nach einer IFNα-Therapie (1, 6, 8, 37, 40, 65, 77, 82, 104, 113, 134, 137, 139, 145, 147, 148, 151, 158, 161, 172, 180, 191) 1. Abdi EA, Venner PM (1986) Immune thrombocytopenia after alpha-interferon therapy in patients with cancer JAMA 255 (14):1878-1879 6. Anderlini P, Buzaid AC, Legha SS (1995) Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon - alpha and chemotherapy for metastatic melanoma Cancer 76 (4):678-679 8. Asnis LA, Gaspari AA (1995) Cutaneous reactions to recombinant cytokine therapy J Am Acad Dermatol 33 (3):393-410 37. Chang L, Liranzo M, Bergfeld WF (1995) Cutaneous side effects associated with interferon-alpha therapy: a review Cutis 56 (3):144 40. Christian MM, Diven DG, Sanchez RL, et al. (1997) Injection site vasculitis in a patient receiving interferon alfa for chronic hepatitis C J Am Acad Dermatol 37 (1):118-120 65. Funk J, Langeland T, Schrumpf E, et al. (1991) Psoriasis induced by interferon alpha Br J Dermatol 125 (5):463-465 77. Greenfield SM, Harvey RS, Thompson RP (1994) Rhabdomyolysis after treatment with interferon alfa Brit Med J 309 (6953):512 82. Guyer DR, Tiedeman J, Yannuzzi LA, et al. (1993) Interferon - associated retinopathy Arch Ophthalmol 111 (3):350-356 104. Köhler U, Linse F, Sebastian G, et al. (2000) Akute Rhabdomyolyse als Komplikation einer Interferon-alpha Therapie bei erythrodermer Mycosis fungoides Zeitschrift für Hautkrankheiten; H+G 3 (75):138-141 113. Lisker-Melman M, Di Bisceglie AM, Usala SJ, et al. (1992) Development of thyroid disease during therapy of chronic viral hepatitis with interferon alpha Gastroenterology 102 (6):2155-2160 134. Nouri K, Valor P, Rodriguez FM, et al. (1996) Interferon alpha-induced intestitial pneumonitis in a patient with cutaneous T - cell lymphoma J Am Acad Dermatol 35 (2 Pt 1):269-270 137. Orlow SJ, Friedman-Kien AE (1992) Cutaneous ulcerations secondary to interferon alpha therapy of Kaposi’s sacoma Arch Dermatol 128 (4):566 139. Pauluzzi P, Kokelj F, Perkan V, et al. (1993) Psoriasis exacerbation induced by interferon alpha. Report of two cases. Acta Derm Venereol 73 (5):395 145. Pigatto PD, Bigardi A, Legori A, et al. (1991) Allergic contact dermatitis from beta-interferon in eyedrops Contact Dermatitis 25 (3):199-200 147. Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa Arch Ophthalmol 113 (8):1041-1044 148. Quesada JR, Gutterman JU (1986) Psoriasis and alpha -interferon Lancet 1 (8496):1466-1468 151. Reinhold U, Hartl C, Hering R, et al. (1997) Fatal rhabdomyolysis and multiple organ failure with adjuvant high-dose interferon alpha in malignant melanoma Lancet 349 (9051):540-541 158. Salzo [sic] S, Gengaro A, Boccoli G, et al. (1990) Primary hypothyreoidism associated with IL-2 and IFNa2-therapy of melanoma and renal carcinoma Eur J Cancer 26 (11-12):1152-1156 161. Schafer M, Messer T, Wegner U, et al. (1999) Psychiatric side efects during adjuvant therapy with interferon-alpha in patients with malignant melanoma: Clinical evaluation as well as diagnostic and therapeutic possibilities Hautarzt 50 (9):654-658 172. Silver RT, Szatrowski TP, Peterson B, et al. (1996) Combined alpha Interferon (rIFNalpha2b) and low dose Cytosine Arabinoside (ARA - C) for PH + chronic phase chronic myeloid leucemia Blood 88; 638 (suppl 1) 180. Tartour E, Schlumberger M, Dorval T, et al. (1995) Endocrine involvement in immunotherapy Ann Endocrinol 56 (2):143-148 191. Wölfer LU, Goerdt S, Schröder K, et al. (1996) Interferon-α-induzierte Psoriasis vulgaris Hautarzt 47 (2):124-128

Anmerkungen Ein Verweis auf die Quelle fehlt.

Sichter (Hindemith), Klgn